HAV vaccine

BIOLOGICAL2 trials

Sponsors

Takeda, International Agency for Research on Cancer

Conditions

HPV InfectionHealthy Volunteers

Phase 3

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

CompletedNCT03525119

TakedaHealthy Volunteers

Start: 2018-05-16End: 2019-07-09Updated: 2022-08-19

Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

Not yet recruitingNCT05173324

International Agency for Research on CancerHPV Infection

Start: 2023-02-01End: 2027-06-30Target: 8000Updated: 2022-08-03

Related Papers

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Vaccine2023-01-1923 citations